1. Medtech Insight
  2. >>Policy & Regulation

Advances In Reimbursement: Prostate Cancer AI Mapping Receives CPT Code

 
• By Hannah Daniel

Avenda’s chief operating officer Brit Berry-Pusey spoke to Medtech Insight about the company’s CPT III code for its prostate cancer mapping AI and how regulatory bodies can align to support innovators.

• Source: Shutterstock

Medtech Insight speaks with industry experts about trends and innovations with potential to transform cancer care.

Avenda Health’s Current Procedural Terminology code for its prostate cancer-mapping artificial intelligence device went into effect in July, moving the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

California Medtech Firms Resolve Patent Dispute Over Delivery Catheters

 
• By Brian Bossetta

Route 92 says it has reached a settlement with Q’Apel Medical over patent claims concerning its Tenzing delivery catheters.

Harbinger Health Targets High-Mortality Cancers First With AI-Driven MCED Platform

 
• By Shubham Singh

With a projected FDA submission within the next two to three years, Harbinger is prioritizing cancers based on lethality, prevalence, and unmet diagnostic need. Pancreatic and biliary cancers – often diagnosed at late stages and lacking established screening programs – will be among the initial targets.

Tariff Pressures Creep Into Dexcom’s Margin Outlook Despite Domestic Manufacturing Shield

 
• By Shubham Singh

Dexcom’s relatively strong position amid tariff-related uncertainty is rooted in its long-standing investments in domestic manufacturing, but raw material inflation is driving cost concerns even in the face of operational efficiencies.